- FDA approves Novartis drug for high blood pressure treatment
- FDA approves Merck's Gardasil for prevention of anal cancer
- New alliance will crack down on adulterated products touting dietary supplement claims
- Mylan's Hyzaar, Cozaar generics receive OK from FDA
- Merck's hepatitis C drug granted priority review by FDA
PITTSBURGH The Food and Drug Administration has approved a generic treatment for organ transplant patients.
Mylan announced Tuesday the approval of tacrolimus capsules in the 0.5-mg, 1-mg and 5-mg strengths, and said it plans to launch the drug immediately. The drug is used to prevent rejection of transplanted organs.
Tacrolimus capsules are a generic version of Astellas’ Prograf. The branded version of the drug and generic versions had sales of around $944 million during the 12-month period ended in June, according to IMS Health.